ART

"Treatment as Prevention (TASP)": Large study fails to show a positive impact on reducing new HIV infections

Cláudio Souza 1 / 4 of the Century Living with HIV
The first large "test and treat" research study as a public health intervention to report its final results found that the strategy failed to reduce new HIV infections in the communities where it was provided. Speaking to 21st International AIDS

Two drugs dolutegravir-lamivudine would be cost-effective and would achieve ample financial savings and facilitate adherence

Cláudio Souza 1 / 4 of the Century Living with HIV
First-line anti-retroviral virologic suppression using a drug regimen of dolutegravir (Tivicay) and lamivudine would be highly cost-effective and could save about $ 500 million in healthcare systems over the course of

Cabotegravir + rilpivirine in Long Injectable Formulation Duration Kill Viral Suppression by 32 weeks

Cláudio Souza 1 / 4 of the Century Living with HIV
The combination of two long-acting injectable antiretroviral drugs - ViiV Healthcare's experimental cabotegravir integrase inhibitor and ITRNN (Non-Analog Reverse Transcription Reverse Transcriptase Inhibitor)

This Site uses Cookies and you may refuse this use. But you may well know what is being recorded in consonance with our política the privatization cidade